<p>NOTE: Pharmacy data through December 31, 2013.</p>1<p> Major fracture includes fracture of spine, humerus, wrist, or hip.</p>2<p> Logistic regression adjusted for age, race/ethnicity, menopausal status, and year of breast cancer diagnosis.</p>3<p> Median (physical activity) = 20.9 metabolic equivalent (MET)-hours/week; median (alcohol intake) = 3.1 g/day.</p><p>Baseline characteristics in relation to major fracture<sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0111477#nt114" target="_blank">1</a></sup> before breast cancer (BC) diagnosis in aromatase inhibitor (AI) users.</p
Aromatase inhibitors (AIs) induce depletion of estrogen levels, causing bone loss and increased frac...
Objective: Baseline bone health in postmenopausal women is poorly characterized in prospective serie...
Aromatase inhibitors (AIs), the standard therapy for estrogen receptor- or progesterone receptor-pos...
<p>NOTE: Pharmacy data through December 31, 2013.</p>1<p> Logistic regression adjusted for age, race...
<p>NOTE: Pharmacy data through December 31, 2013.</p>1<p> Osteoporosis defined by ICD-9 code (733.00...
Background Aromatase inhibitors (AIs) used in breast cancer induce loss in bone mineral density (BMD...
Background. Aromatase inhibitors (AIs) used in breast cancer induce loss in bone mineral density (B...
A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) u...
A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) u...
<p>NOTE: Pharmacy data through December 31, 2013; Missing data for entire cohort: menopausal status ...
FRAX was developed to predict 10‐year probability of major osteoporotic fracture (MOF) and hip fract...
FRAX was developed to predict 10-year probability of major osteoporotic fracture (MOF) and hip fract...
BACKGROUND: The impact of long-term adjuvant therapy with aromatase inhibitors (AIs) on vertebral f...
OBJECTIVE: Baseline bone health in postmenopausal women is poorly characterized in prospective serie...
Importance: Aromatase inhibitors induce a profound depletion in serum estrogen levels. Postmenopausa...
Aromatase inhibitors (AIs) induce depletion of estrogen levels, causing bone loss and increased frac...
Objective: Baseline bone health in postmenopausal women is poorly characterized in prospective serie...
Aromatase inhibitors (AIs), the standard therapy for estrogen receptor- or progesterone receptor-pos...
<p>NOTE: Pharmacy data through December 31, 2013.</p>1<p> Logistic regression adjusted for age, race...
<p>NOTE: Pharmacy data through December 31, 2013.</p>1<p> Osteoporosis defined by ICD-9 code (733.00...
Background Aromatase inhibitors (AIs) used in breast cancer induce loss in bone mineral density (BMD...
Background. Aromatase inhibitors (AIs) used in breast cancer induce loss in bone mineral density (B...
A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) u...
A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) u...
<p>NOTE: Pharmacy data through December 31, 2013; Missing data for entire cohort: menopausal status ...
FRAX was developed to predict 10‐year probability of major osteoporotic fracture (MOF) and hip fract...
FRAX was developed to predict 10-year probability of major osteoporotic fracture (MOF) and hip fract...
BACKGROUND: The impact of long-term adjuvant therapy with aromatase inhibitors (AIs) on vertebral f...
OBJECTIVE: Baseline bone health in postmenopausal women is poorly characterized in prospective serie...
Importance: Aromatase inhibitors induce a profound depletion in serum estrogen levels. Postmenopausa...
Aromatase inhibitors (AIs) induce depletion of estrogen levels, causing bone loss and increased frac...
Objective: Baseline bone health in postmenopausal women is poorly characterized in prospective serie...
Aromatase inhibitors (AIs), the standard therapy for estrogen receptor- or progesterone receptor-pos...